Combination therapy of weekly lzomib, lenalidomide, dexamethasone is used for patients with newly diagnosed multiple myeloma. Recent studies show that adding daratumumab to this weekly dosing can increase the safety and efficacy of the therapy. This study aims to evaluate the impact of adding daratumumab to the existing weekly combination therapy for multiple myeloma.
This clinical and correlative pilot study included a total of 41 patients with newly diagnosed multiple myeloma. The participants were assigned to receive eight 28-day cycles of intravenous therapy followed by intravenous daratumumab. The primary outcome of the study was the minimal residual disease (MRD) rate, along with safety and tolerability.
Of 41 patients included in the study, 20 (49%) had high-risk multiple myeloma. The primary endpoint, marked by MRD negativity in bone marrow, was achieved in 29 of 41 patients (71%). The median time to MRD negativity was 6 cycles. The overall response rate and partial/complete response rate were 100% and 95%, respectively. At 1 year of follow-up, the progression-free survival rate and overall survival rate were 98% and 100%, respectively.
This trial was deemed successful and concluded that adding daratumumab to carfilzomib-lenalidomide-dexamethasone therapy was associated with high rates of MRD negativity and survival.
Ref: https://jamanetwork.com/journals/jamaoncology/article-abstract/2778195?resultClick=1
